Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons

Autor: Carine Claeys, Khalequ Zaman, Ghassan Dbaibo, Ping Li, Allen Izu, Pope Kosalaraksa, Luis Rivera, Beatriz Acosta, Maria Luisa Arroba Basanta, Asma Aziz, Miguel Angel Cabanero, Vijayalakshmi Chandrashekaran, Bartholomew Corsaro, Luis Cousin, Adolfo Diaz, Javier Diez-Domingo, Ener Cagri Dinleyici, Saul N Faust, Damien Friel, Jose Garcia-Sicilia, Grace D Gomez-Go, Maria Liza Antoinette Gonzales, Stephen M Hughes, Teresa Jackowska, Shashi Kant, Marilla Lucero, Ludovic Malvaux, Josep Mares Bermudez, Federico Martinon-Torres, Mariano Miranda, May Montellano, Maria Amor Peix Sambola, Roman Prymula, Thanyawee Puthanakit, Renata Ruzkova, Iwona Sadowska-Krawczenko, Ignacio Salamanca de la Cueva, Etienne Sokal, Jyoti Soni, Henryk Szymanski, Angels Ulied, Anne Schuind, Varsha K Jain, Bruce L Innis, Beatriz Acostas, Arshad Amanullah, Miguel Ariza, Milagros Bautista, Ashish Bavdekar, Bhavesh Bodalia, Lulu C Bravo, Jerzy Brzostek, Ian Caldwell, Alfonso Carmona, Jasur Danier, Ana Isabel Diaz Cirujano, Martine Docx, Daniel Drazan, Andrzej Galaj, Fermin Garcia Rodriguez, Trevor Gooding, Mustafa Hacimustafaoglu, Paul Heath, Paul Heaton, Sanjay Lalwani, Jennifer Langlands, Karl Logghe, Jolanta Mantyka, Damien McNally, Edyta Miszczak-Kowalska, Simon Royal, Benjamin Sablan, Matthew Snape, Richard Tomlinson, Marc Verghote, Andre Vertruyen, Marie Wheeler

Publikováno v: LANCET CHILD & ADOLESCENT HEALTH
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

BackgroundDespite the importance of vaccinating children younger than 5 years, few studies evaluating vaccine prevention of influenza have been reported in this age group. We evaluated efficacy of an inactivated quadrivalent influenza vaccine (IIV4)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b340ce6383216acb8bc04f9d8ea904
https://pubmed.ncbi.nlm.nih.gov/30169261

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

Autor: Jacek Wysocki, Tino F. Schwarz, Dominique Descamps, Karin Schulze, Grégory Catteau, Achim Schneider, Marek Spaczyński, Florence Thomas, Andrzej Galaj, Sylviane Poncelet

Publikováno v: Human Vaccines. 7:958-965

The HPV-16/18 AS04-adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) has been shown to induce a robust immune response in women aged 15–55 years (103514/NCT00196937). This follow-up study is the first report of persistence of immune resp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85a0082fe330afe2e25728994feb5897
https://doi.org/10.4161/hv.7.9.15999

Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age

Autor: Birgit Thierry-Carstensen, Andrzej Galaj, Jacek Wysocki, Helena Käyhty, Jacek J Pietrzyk, Ewa Majda-Stanisławska, Jerzy Pejcz, Anders Mørup Jensen

Publikováno v: Vaccine. 26(41)

In a phase III, double blind, randomized, noninferiority, multi-centre clinical trial, 817 infants were included and randomly assigned to vaccination with DTaP-IPV(Vero) (N=410) or DTaP-IPV(Mkc) (N=407) vaccines (Statens Serum Institut (SSI), Denmark

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560545dc4dd134c36fb62010793a8924
https://pubmed.ncbi.nlm.nih.gov/18675870